Inhalable Expression Vector for Lung Tumor Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating lung tumors lack effective ways to administer plasmids directly to the lungs, limiting the treatment options for lung cancers such as NSCLC and SCLC.
Innovation Solution
An inhalable dosage form comprising an expression vector with a nucleic acid sequence encoding GM-CSF and bi-functional short hairpin RNA (bi-shRNA) capable of inhibiting furin expression via RNA interference, combined with stabilizing excipients like trehalose, is developed for pulmonary delivery using a dry powder formulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If plasmids are administered systemically to treat lung tumors, then the treatment can reach tumor cells, but the plasmids cannot be effectively delivered directly to the lungs with high local concentration
Solution Approach 1:
The patent uses inhalable particles as an intermediary delivery vehicle to transport plasmids directly to the lungs. The particles serve as a mediator between the plasmid and lung tissue, enabling targeted delivery that systemic administration cannot achieve. This resolves the contradiction by providing a practical administration method (inhalation) that achieves high local concentration.
2Reliability
If RNA interference is used to inhibit furin expression, then immune response is enhanced, but the stability and delivery of RNA molecules to lung tissue is challenging
Solution Approach 1:
The patent encapsulates RNA interference molecules within inhalable particles with protective shells or matrices. This physical encapsulation protects the RNA from degradation while maintaining its biological activity, enabling stable delivery to lung tissue. The particle structure acts as a protective barrier that preserves RNA integrity during administration and delivery.
3Productivity
If multiple genes are targeted simultaneously with RNAi, then treatment efficacy is improved, but the complexity of the delivery system increases
Solution Approach 1:
The patent combines multiple RNA interference molecules targeting different genes (including furin and other cancer-related genes) into a single inhalable particle formulation. This merging approach allows simultaneous delivery of multiple therapeutic agents through one administration act, improving treatment efficacy while avoiding the complexity of multiple separate delivery systems.
Solution Approach 2:
The inhalable particle delivery system is designed as a universal platform that can accommodate multiple different RNA interference molecules. This multi-functional delivery vehicle can target various genes involved in lung cancer pathogenesis simultaneously, making the system adaptable to different treatment needs without requiring separate specialized delivery mechanisms for each target.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for targeted treatment of lung tumors by delivering the expression vector directly to the lungs, effectively inhibiting furin expression and enhancing immune response, thereby treating primary lung cancers and metastatic tumors.
Implementation Method 1
a second insert comprising a nucleic acid sequence encoding at least one bi-functional short hairpin RNA (bi-shRNA) capable of hybridizing to a region of a mRNA transcript encoding furin, thereby inhibiting furin expression via RNA interference
Data Source
AI summary
The present disclosure provides composition formulated into inhalable dosage forms for treating a tumor or cancer in the lung. The compositions can be lyophilized compositions formulated for pulmonary delivery via a device.